Trial Profile
A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, 2-Arm Study to Show Superiority of the Oral Contraceptive SH T00658ID Over Ortho Tri-Cyclen Lo on Hormone Withdrawal-Associated Symptoms After 6 Cycles of Treatment.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Estradiol valerate/dienogest (Primary) ; Ethinylestradiol/norgestimate
- Indications Pregnancy
- Focus Therapeutic Use
- Acronyms HARMONY-I
- Sponsors Bayer
- 05 May 2012 Results presented at the 60th Annual Meeting of the American College of Obstetricians and Gynecologists.
- 20 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 20 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.